You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers uncovered rare, damaging mutations in genes involved in early brain development among 22 percent of 381 sporadic congenital hydrocephalus cases.
The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.
Researchers profiled T cells in the cerebrospinal fluid of healthy individuals and multiple sclerosis patients using single-cell RNA-seq and T cell receptor sequencing.
In Genome Biology this week: improved reference genome for the Asian tiger mosquito Aedes albopictus, links between Ebola variants and outcomes, and more.
In Genome Biology this week: analysis of tuberculosis samples from the 1600s, tool to detect variants affecting RNA-binding protein activity, and more.
A saliva-based test for COVID-19 that got help from the National Basketball Association has received Emergency Use Authorization, according to the Wall Street Journal.
The test could be used in most high-complexity labs because it has been authorized for use with different combinations of frequently used reagents and instruments.
Regular SARS-CoV-2 testing could limit COVID-19 cases on university campuses but results might vary based on the schools' behavioral interventions.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.